The role of visfatin in NAFLD has been evaluated, but the results were inconsistent [11–13], and it remains unclear whether visfatin contributes to hepatic insulin resistance and inflammation. The gene discussed is NAMPT; the disease is metabolic dysfunction-associated steatotic liver disease.